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Complex cellular and molecular events occur in the neurovascular unit after stroke, such as 
Blood-Brain Barrier (BBB) dysfunction and inflammation that contribute to neuronal death, 
neurological deterioration and mortality. Caveolin-1 (Cav-1) has distinct physiological functions 
such as caveolae formation associated with endocytosis and transcytosis as well as in signaling 
pathways. Cav-1 has been proposed to be involved in BBB dysfunction after brain injury however, 
its precise role is poorly understood. The goal of this study was to characterize the expression 
and effect of Cav-1 deletion on outcome in the first week after a transient Middle Cerebral Artery 
Occlusion stroke model (tMCAO). We found increased Cav-1 expression in new blood vessels in 
the lesion and in reactive astrocytes in the peri-lesion areas. In Cav-1 KO mice, the lesion volume 
was larger and the behavioral outcome worse than in WT mice. Cav-1 KO mice exhibited reduced 
neovascularization and astrogliosis without formation of a proper glial scar around the lesion 
compared to WT mice at 3 days post injury coinciding with aggravated outcomes. Altogether, 
these results point towards a potential protective role of endogenous Cav-1 in the first days after 
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Stroke is the third cause of death worldwide and the first cause of acquired disability in adults1. 
Overall, ischemic strokes represent approximately 85% of strokes2. Intravenous administration of 
recombinant tissue plasminogen activator was approved for the treatment of ischemic stroke in 
the United States in 1996 and by the European Union in 2003. More recently, it has been 
demonstrated that patients with ischemic stroke caused by a proximal occlusion in the anterior 
circulation benefit from endovascular thrombectomy3. Despite these improvements, an important 
number of patients do not benefit sufficiently from these treatments and remain disabled. 
Therefore, research aimed at discovering alternative therapies needs to be continued and 
neuroprotective agents should be re-examined as additional therapies to recanalization. An 
emerging concept is that protection could be achieved by studying and influencing the molecular 
mechanisms triggered not only in neurons after stroke but also in other cell types that likely 
participate in neuronal survival or play a role in repair mechanisms4. As such, endothelial cells 
and astrocytes, as part of the neurovascular unit (NVU)5 could play a major role in preserving or 
recovering brain functions after stroke. The term neurovascular unit (NVU) alludes to brain 
blood vessels and emphasises the close physical and functional connection between 
brain tissue and blood vessels. Brain vasculature is anatomically distinct consisting of pericytes 
and astrocyte endfeet in addition to endothelial cells. Further, microglia and nerve endings 
contact brain vessels that collectively form the NVU. The BBB restricts passage of molecules 
from the blood circulation to the brain tissue as well as coordinating the exchange of ions, 
molecules and cells between the blood and brain. The presence and maintenance of the barrier 
properties by the NVU are critical for brain homeostasis and neuronal functioning6. After a stroke, 
brain tissue follows a remodeling process with neo-vascularization in the lesion core and 
formation of a glial scar around the core of the lesion7, 8. Therefore, NVU function is also probably 
central for brain tissue remodeling and potentially for brain plasticity and recovery. 
Caveolins are transmembrane proteins involved in the formation of caveolae (plasma membrane 
invaginations or vesicles of 50 to 100 nm in size that serve as membrane organizing centers), 
 
 
macromolecular transport and permeability, as well as signal transduction. Currently, there are 
three members of the caveolin family, Cav-1, Cav-2 and Cav-3, with highly conserved sequences 
across species9. In the brain, Cav-1 was initially believed to be restricted to endothelial cells, 
however it was then found in astrocytic cultures10, 11 and in juvenile rat astrocytes after Traumatic 
Brain Injury (TBI)12. Caveolin proteins are key modulators of a variety of neuronal intracellular 
signaling pathways13. In caveolae, Caveolin-1 is the major multifunctional scaffolding protein that 
provides a docking site to anchor various proteins, thereby regulating a variety of signaling 
molecules and modulating downstream signaling pathways14. Caveolae are present in most cell 
types but are particularly abundant in endothelial cells, smooth and striated muscle cells, 
adipocytes14 and astrocytes and neurons. Recently, new evidence has appeared on the beneficial 
role of caveolins in kidney, hind limb and cardiac ischemia models, indicating a ubiquitous role of 
caveolins in ischemic cell death7. Caveolae formation regulates several signaling pathways by 
caveolin oligomerization or directly by caveolin proteins via their scaffolding-binding domain15. 
Cav-1 for example, is known to down-regulate the activation of endothelial nitric oxide synthases 
(eNOS) resulting in inhibition of nitric oxide (NO) production16. Another study showed that Cav-1 
activates matrix metalloproteinases (MMPs), especially MMP9 and MMP2, which are involved in 
the BBB opening after injury17, 18. The absence of Cav-1 could therefore limit the consequences 
of the lesion on BBB properties by a decrease of NO synthesis, limiting MMP9 production post-
injury and preventing BBB rupture. However, the exact role of Cav-1 in modulating BBB integrity 
after brain injury is controversial. Notably, the expression of Cav-1 in brain microvessels is 
downregulated at three different time points after reperfusion after ischemia17. On the contrary, 
other immunofluorescence studies revealed an increase in Cav-1 expression in ischemic rat 
brains or an increase in the number of endothelial caveolae in a mouse model of ischemia and 
reperfusion19, 20. Moreover, Cav-1 deficiency increased cerebral ischemic injury in a permanent 
distal MCAO model19. Therefore, Cav-1 is likely to play an important role in NVU function via its 
involvement in BBB permeability but this probably depend on the injury model. Furthermore, it is 
now well established that the same protein can have several roles depending on its location with 
 
 
respect to the lesion core and the time after the injury14, 21. Here, we address the role of Cav-1 by 
histological and immunohistochemical analysis of the NVU in the lesion core and perilesional 
tissue (penumbra) focusing on the new role of astrocytes after stroke and behavioral evaluation 
post-stroke which has never been reported in Cav-1 KO and WT mice from 6 hours to 7 days 
post-injury in a transient middle cerebral occlusion model.   
 
 
Material and Methods 
Animal experiments and care complied with the Federal regulations and guidelines of the Swiss 
Veterinary Office and were approved by the Animal Care and Use Committee and registered as 
license VD2017.5. Animal reporting was according to the ARRIVE guidelines.  
 
Animal groups 
We purchased Cav-1 KO mice in a C57Bl/6J background from Jackson Laboratory (JAX stock 
#007083) and bred them on site. We purchased male C57Bl/6J wild type (WT) mice (6 weeks-
old) from Charles River. All animals used in experiments were housed for at least one week in a 
temperature-controlled animal facility on a 12-hours light-dark cycle with ad libitum access to food 
and water. Home cages contained standard bedding and enrichment material.  
In our experimental design, we performed two sets of experiments with a total of 25 WT and 28 
Cav-1 KO mice (Table 1):  
 WT Cav-1 KO 
 tMCAO Sham tMCAO Sham 
Total 17 8 21 7 
Sample Collection: Total 8 3 9 2 
- Completed 8 3 7 2 
- Terminal endpoint reached 0 0 2 0 
Behavioral and lesion size study: Total 9 5 12 5 
- Completed 7 5 3 5 
- Terminal endpoint reached 1 0 6 0 
- Found dead 1 0 3 0 
 
1) Behavioral evaluation and lesion size measurements with n=9 for WT and n=12 Cav-1 KO for 
tMCAO procedures. Sham experiments were also conducted in parallel with n=5 WT and n=5 
 
 
Cav-1 KO mice. Animals were randomly assigned to sham or tMCAO procedures. Results of the 
sham animals are available as supplementary information online. 
2) Immunofluorescence experiments with n=14 WT and n=17 Cav-1 KO animals collecting two to 
three different samples at the three different time points (sham and tMCAO at 6 hours, 1 and 3 
dpi).  
We tested animals in several behavioral tests every day after tMCAO and evaluated lesion size 
at 7 dpi. For immunofluorescence, animals were perfused (see below) at 6 hours, 1 and 3 dpi. 
Our veterinary authority approved the following humane termination endpoints: loss of righting 
reflex from 24h post-injury, status epilepticus, body weight loss of more than 25%. In the 
experiments described here, we had to terminate nine mice (1 WT and 8 Cav-1 KO mice). 
 
 
Transient Middle Cerebral Artery Occlusion (tMCAO) model 
We used the tMCAO model with the intraluminal suture method via the common carotid artery as 
previously described22. Briefly, mice were anesthetized with isoflurane (3% induction, 1.5-2% 
maintenance) and body temperature was maintained throughout surgery at 37±0.5°C with a 
heating pad (DC Temperature Controller, FHC). We monitored Cerebral Blood Flow (CBF) by 
Doppler flowmetry (Perimed system) using a flexible probe fixed onto the skull (1 mm posterior 
and 6 mm lateral from bregma). Baseline CBF was obtained before the carotid exposure. We 
induced ischemia by introducing an 11-mm silicone-coated 8–0 filament (Doccol Corp, USA) from 
the left common carotid artery into the internal carotid artery, advancing until we felt a resistance. 
We left the filament in place for 35 min. Successful ischemia was obtained when CBF during the 
tMCAO was below 20% of the baseline measurement and reperfusion had to achieve 50% of the 
baseline measurement. We excluded two WT animals and one Cav-1 KO from the experiment for 
not achieving reperfusion. We performed sham surgery under anesthesia, which consisted of 
placing the Doppler probe onto the skull and opening the neck to dissect the carotid arteries 
without filament insertion. After surgery, animals were maintained overnight in an incubator at 
 
 
28°C. We assessed the coat, eyes and nose, neurological deficit, epileptic seizures, body weight 




We assessed the Neuroscore each day after injury; a modified version of the Bederson scale23, 
according to the following ratings: no observable deficit: 0; failure to extend the right forepaw: 1; 
circling: 2; humane endpoint reached or death: 3. Intermittent circling was graded as 1.524. 
Rotarod test 
We modified all behavioral tests assessing post-stroke deficits from Balkaya et al.25. 
For the rotarod test, briefly, mice were placed on an accelerating rotating cylinder (UgoBasile), 
and the longest latency to fall over three trials of maximum 900 seconds was recorded24. We 
trained mice three days before injury and tested on days 1, 3, 5 and 7 post-injury. We express 
performance as the percentage of the best performance from the training. Mice excluded before 
the end of the experiment due to sacrifice for humane reasons (see previously) were allocated a 
minimum score of 0 seconds in the following test-days to limit survival bias in the graphical 
representation and statistics.  
Adhesive Removal test 
The animal was placed in a transparent Perspex box for 60 seconds for habituation. For the test, 
we applied a small piece of adhesive tape (rectangular piece 3 x 4 mm cut from Time®Tape, 
TimeMed Inc) under the forepaws while restraining the mouse. The order of placement (right or 
left forepaw first) was alternated for each trial. Directly after placing both adhesives, the 
experimenter pressed both forelimbs simultaneously to minimize bias. We then placed the mouse 
back into the Perspex box for 120 seconds and the time to contact and remove each adhesive 
tape was recorded and blindly scored using the Observer software (Noldus). Contact occurred 
when the paw was shaken or the mouth was used to touch the adhesive. We performed three 
consecutive trials for each mouse, every day of training or testing. Mice were trained three days 
 
 
before injury and tested on days 2, 4 and 6 dpi. SG and CB scored blindly the time to contact and 
remove the adhesive on ipsilateral and contralateral paws and pooled data. We gave the 
maximum score of 120 seconds to mice excluded before the end of the experiment because of 
death or sacrifice for humane reasons to limit survival bias in the representation and the statistics.  
 
Lesion volume measurement 
We froze brains in liquid nitrogen vapor after sacrifice. We collected 20 µm thick coronal sections 
using a cryostat (Leica CM3050) on Superfrost Plus® slides. Sections were stained with cresyl 
violet, then scanned with a stereomicroscope (Nikon SMZ 25) at 5x magnification and finally 
analyzed with ImageJ/FIJI software. CB quantitated infarction volumes, blinded to the animal 
group, on 12 coronal sections 720 μm apart. Infarction volumes were calculated by multiplying 
the sum of the infarcted areas on each section by the spacing distance. 
 
Immunofluorescence staining and image analysis 
For tissue collection, mice were transcardially perfused first with PBS and then with 4% PFA at 
4°C at a speed of 10 mL/min. Following overnight post-fixation in PFA, we cryoprotected brains 
in PBS with 30% sucrose for 48h, then froze them in isopentane cooled on dry ice. We collected 
25 µm thick coronal sections using a cryostat and into cryoprotectant solution. 
Immunofluorescence staining was performed on free-floating sections with antigen retrieval with 
cold 33% acetic acid + 66% ethanol, blocked with 1% bovine serum albumin (BSA, Sigma Aldrich) 
+ 5% horse serum + 0.1% Triton X100 solution for 1 hour at room temperature. Primary antibodies 
used were: Rabbit anti-Cav-1 (1:500, Abcam, cat # ab2910), Rat anti-CD31 (1:100, BD 
Biosciences, cat # 550274), Rabbit anti-GFAP (1:2000, Millipore Merck, cat # AB5804), Mouse 
anti-GFAP (1:2000, Millipore Merck, cat # MAB3402), Mouse anti-GS (1:1000, Millipore Merck, 
cat # MAB302), Mouse anti-MAP2 (1:500, Millipore Merck, cat # MAB3418), Rabbit anti-Ki67 
(1:200,Thermofisher, cat # RM-9106-R7). Primary antibodies were incubated in antibody solution 
(1% BSA + 0.3% Triton X100 in PBS) overnight at 4ºC. Appropriate secondary antibodies, all 
 
 
Alexa Fluor® labeled (Invitrogen) were incubated in antibody solution together with DAPI as 
nuclear counterstain for one hour at room temperature. Sections were mounted on SuperFrost 
Plus® slides (Fischer Scientific) with FluorSave medium (Calbiochem) and coverslipped.  
We captured images of whole-coronal brain sections using a slide-scanner (Zeiss AxioScan Z1) 
at 10x magnification. We acquired stained caveolin proteins and other cellular markers in the 
ipsilateral and contralateral striatum to the lesion with a confocal microscope (Zeiss LSM 710 
Quasar) at 67x magnification.  
Images for the vessel density analysis and the quantification of Ki67 were acquired with the same 
confocal microscope at 40x magnification. Vessel density analysis was performed using the 
vessel density plugin available for Fiji. The quantification of Ki67 positive nuclei was done on 
averaged z-projections using Fiji on stacks of 15 to 17 images with 1µm spacing on 3 images per 
animal with 3 animals in each group (WT and Cav-1 KO). 
Stacks of images for the morphological analysis were acquired with an epifluorescence 
microscope (Zeiss Imager Axio Z1) at 40x magnification. The morphological analysis of astrocytes 
was performed by TC using Fiji’s bandpass and unsharp mask filtering, binarization, 
skeletonization and skeleton analysis as described in Morrison et al.26 on the averaged z-
projections on n=4 areas per animal with 3 animals per group. Quantification of the Ki67 positive 
nuclei and analysis of the morphology of astrocytes were performed blinded to the group of mice. 
 
Western Blots 
Protein were prepared from frozen cryostat sections collected for WT Sham and tMCAO where 
ischemic was separated from contralateral non-ischemic hemisphere of the brain. Samples were 
homogenized in cold modified Bonny lysis buffer containing protease and phosphatase inhibitors. 
Protein quantification was performed with a Bradford Kit (Bio-Rad). Proteins were then separated 
on gels (NuPAGE 10% Bis-Tris Gel, cat # NP0302BOX) and transferred to PVDF membranes. The 
membranes were then placed in blocking solution (Li-Cor Odyssey Blocking buffer, Part No:927-
4000) for 1 hour. The membranes were incubated with Cav-1 (1:1000, Abcam, cat # ab2910) and 
 
 
α-tubulin (alpha-tubulin (TU-02), 1:2000, Santa Cruz Biotech, cat # sc-8035) primary antibody 
overnight at 4°C. Afterward, the membranes were washed in PBS + 0.05% Tween and finally 
incubated 1 hour at room temperature with IR-conjugated secondary antibodies (Odyssey 
IRDye® Goat anti-Mouse 800 CW and Goat anti-Rabbit 680LT, Li-Cor). The Li-cor system was 
used to detect bound primary antibody. Western blots for Cav-1 were quantitated with Fiji software 
using the mean gray value of each band and compared using one-way ANOVA. 
 
Statistical analysis 
We performed all measurements and analyses without knowledge of the group and statistical 
analyses using Prism software (GraphPad). We represent data as box and whiskers plots, 
showing the median, minimal and maximal values as well as individual data points. Bar graphs 
are expressed as mean ± Standard Deviation (SD) and individual data points are displayed. We 
compared the survival of the two groups statistically with the Mantel-Cox test. We carried out two-
group comparisons with the Student unpaired t-test after testing Gaussian distribution and similar 
standard deviation for both populations. We analyzed behavioral tests performed with the same 
groups of animals over several days with 2-way ANOVA for repeated measures with Holm-Sidak 
multiple comparison post-hoc test. Statistical significance was set at * p<0.05, ** p<0.01, *** 





Expression of Caveolin-1 in endothelial cells and reactive astrocytes 
We investigated the expression and cellular localization of Cav-1 in ipsilateral and contralateral 
hemispheres to the lesion using Western Blot and double-immunostaining with anti-CD31 
(endothelial cell marker), anti-Glutamine Synthetase (GS, pan-astrocyte marker) or anti-Glial 
Fibrillary Acidic Protein (GFAP, reactive astrocyte marker) and anti-Cav-1 in WT coronal brain 
sections 3 days after tMCAO (Figure 1). Quantification of Cav-1 protein in the Western Blot 
(Figure 1a) revealed an up-regulation of Cav-1 in the ipsilateral side compared to the contralateral 
side to the lesion using one-way ANOVA (F=11.45 , p=0.0090). We found a co-localization of 
Cav-1- and CD31 immunolabeling, in the striatum ipsilateral and contralateral to the lesion (Figure 
1c, left panel compared to Figure 1d, right panel). Cav-1 also co-localized with GS positive 
astrocytes in the ipsilateral striatum and to a lesser extent on the contralateral side to the lesion 
(Figure 1e-f). Finally, in the peri-lesion area in the ipsilateral hemisphere (Figure 1g, left panel), 
we observed Cav-1 in some reactive astrocytes, stained by GFAP-immunoreactivity. In the 
contralateral hemisphere (Figure 1h, right panel), only a few astrocytes in the striatum were GFAP 
positive, but co-localization with Cav-1 was observed here too. Negative controls on Cav-1 KO 
samples and triple staining of Cav-1 with microglial marker Iba-1 and neuronal marker NeuN 
available online in supplementary (respectively Supplementary figures 1 and 2) 
These results provide evidence of the modification of Cav-1 expression in the neurovascular unit 
after stroke. More specifically, we saw enhanced Cav-1 in endothelial cells in the lesion and 
interestingly, presence in reactive astrocytes in WT animals after stroke.  
Outcome assessment 
Assessment of survival and lesion size 




In both experimental groups (WT and Cav-1 KO) not all animals reached the set sacrifice time 
point of 7 days post-injury (dpi). We sacrificed some animals, mainly from the Cav-1 group, earlier 
according to predetermined termination criteria or found them dead. Following 35 min tMCAO, 
most of the WT mice survived 7 days (7/9). However, Cav-1 KO mice showed a significantly 
decreased survival rate compared to WT (3/12) quantified using a Kaplan-Meier curve (Figure 2a, 
Mantel-Cox test (χ2=4.603, p=0.0319)). It is to note that the loss of Cav-1 did not pre-dispose mice 
to lethality without the tMCAO. All animals exposed to sham injuries (anesthesia and carotid 
dissection without insertion of the filament) survived for the planned duration of 7 days after 
injuries and performed as well as WT in the behavioral tasks (Supplementary Figure 3). 
In agreement with the decreased survival rate, the lesion volume measured on cresyl violet 
stained sections at the time of sacrifice (3 to 7 dpi) was significantly larger in the Cav-1 group 
compared to WT (65.73 ± 27.33 mm3 (mean ± SD) versus 33.33 ± 18.67 mm3 respectively Figure 
2b, unpaired t-test (t= 2.44, p=0.0326)). The increased volume also persisted when we took into 
account the edema by measuring the size of the ischemic lesion compared to the total size of the 
brain. 
The evolution of the lesion pattern over time after reperfusion at 6h, 24h and 3 days was evaluated 
in WT and Cav1-KO mice using microtubule associated protein 2 (MAP-2) staining of neurons 
(Figure 2c). A decreased area of MAP-2-labeling revealed the lesion core highlighted by a yellow 
dotted line. The surface area of decreased MAP-2 staining appeared already larger in Cav-1 KO 
animal sections compared to WT as early as 6 hours post-injury. In the Cav-1 KO sections, we 
observed decreased MAP-2 labeling in the striatum as well as in a large part of the cortex at 6h 
after reperfusion while, in the WT group at 6 hours after tMCAO, the decrease in MAP-2 staining 
was limited to the striatum.  
Overall, these results suggest that the presence of Cav-1 attenuated and/or delayed the 




Assessment of sensorimotor deficits 
We determined general neurological status (righting reflex, forepaw extension and spontaneous 
locomotor activity) using the neuroscore, a modified version of the Bederson scale23. The 
neuroscore was assessed every single day after the stroke (see supplementary data, 
Supplementary Figure 4), however only the scores obtained at 1, 4 and 7 dpi are shown in Figure 
3a for clarity. As outlined in the methods, behavioral performances were analyzed statistically with 
ANOVA, using either days or experimental groups as variables. Globally, there was a significantly 
higher proportion of animals exibiting neuroscore improvement over time after injury in WT mice 
compared to KO mice (two-way ANOVA with repeated measures, percentage of total variation: 
8.061%, p<0.0001). The Cav1-KO mice showed the opposite trend, with a higher number of 
animals developing a more severe score than the WT group (Figure 3a). There was a signifcant 
difference between experimental groups: WT and Cav-1 KO (percentage of variation: 13.02%, 
p=0.0367) as well as on the interaction between experimental group and day variables 
(percentage of variation: 6.88%, p=0.0001). 
The time spent on the rotarod before falling is presented as percentage of the best perfomance 
(or longest latency to fall) measured before stroke onset for each animal in Fig 3b. We recorded 
rotarod performance at 1, 3, 5 and 7 dpi (Figure 3b). At one dpi, both WT and Cav-1 animals 
performed below 50% of their best baseline. On day 3 dpi, WT animals improved to 73.14 ± 34% 
(mean ± SD) whereas Cav-1 KO animals only improved to 45.43 ± 45%. WT animals performed 
similarly at days 5 and 7 dpi while Cav-1 KO performance decreased due to the increased 
mortality. The difference between experimental groups (WT versus Cav-1 KO animals) was 
significant with the two-way ANOVA with repeated measures (percentage of total variation: 
13.79%, p=0.0117).  
We used the adhesive removal test to assess fine sensorimotor skills involving mouth and digits. 
We present the time to contact or remove the adhesive as the difference between the testing time 
and the best baseline time measured before stroke onset for each animal, with results from the 
paw ipsilateral to the lesion pooled with the results of the contralateral paw. The mean time to 
 
 
contact (Figure 3c) and remove (Figure 3d) the adhesive was increased for both groups at 3 dpi. 
Moreover, Cav1-KO mice on average took longer to contact and remove the adhesive than WT 
mice at this time-point. The ANOVA with repeated measures for contact times was significant 
between days of testing post-stroke (percentage of variation: 16.24%, p<0.0001) and between 
WT and Cav-1 KO groups (percentage variation 6.031%, p=0.0293) but also the interaction 
between days and experimental groups was significantly different (percentage of variation: 
4.117%, p=0.0166). Significant differences for the removal time were also seen for the effect of 
days (percentage of variation: 3.987%, p=0.0202) and experimental groups (percentage of 
variation: 15.48%, p=0.0018) but not for the interaction of the two variables.  
In summary, Cav-1 KO mice exhibit worse functional outcome than WT mice in accordance with 
the larger lesion volumes observed. All together, these results suggest a protective role for Cav-
1 protein after stroke.  
 
Assessment of neovascularization 
In Figure 4a and b we show CD31-labeling (red) having brighter staining in the lesion core 
compared to the contralateral area at 3 dpi in both WT and Cav-1 KO mice, suggesting an 
increase of blood vessel CD31-reactivity (Figure 4a, b). This enhanced labeling could reflect 
neovascularization so we used Ki67, a marker of cell proliferation in combination with CD31 to 
test this. Coronal brain sections showed Ki67 staining in the ischemic lesion in both groups (Figure 
4c, d). Interestingly, the number of Ki67 positive nuclei appeared higher in WT animals (Figure 
4c) compared to Cav-1 KO animals (Figure 4d). We confirmed this on images at 40x magnification 
where we saw a significantly higher number of CD31 positive cells with Ki67 labeled nuclei (Figure 
4e,g), in WT than in Cav-1 KO mice, suggesting reduced cell proliferation in Cav-1 KO after stroke. 
On the vessel density analysis (Figure 4f), more area of vasculature was found in the WT 
compared to the Cav-1 KO images (unpaired t-test: t=3.485, p=0.0019). On quantification (Figure 
4g), the number of Ki67-positive nuclei per area was significantly higher in WT with 49.33 ± 12.1 
 
 
Ki67-positive nuclei (mean ± SD) compared to Cav-1 KO animals, 21.56 ± 6.15 Ki-positive nuclei 
(unpaired t-test, t=6 and p<0.0001) in images at 20x magnification. Similarly, the number of Ki67-
positive nuclei in endothelial cells was significantly higher with 21.1 ± 4.5 positive nuclei per area 
for the WT and 13.44 ±3.82 (Mean ±SD) for the Cav-1 KO (t-test, t=2.498, p=0.0238).  
Our results show that the absence of Cav-1 affects the number of proliferating endothelial cells in 
the lesion and this may impair the process of neovascularization observed in the core of the lesion 
after stroke.  
 
Cav-1 and astrocyte reactivity 
We observed the presence of Cav-1 in reactive astrocytes after stroke (Figure 1c), and went on 
to determine for the first time possible effects of Cav-1 absence on astrogliosis and formation of 
the glial scar. We performed double labelling with MAP-2 (green) to delineate the lesion area and 
GFAP (red) to stain reactive astrocytes in brain sections from WT and KO animals collected at 
6h, 24h and 3 dpi, to establish a time-course of the astrocyte changes in relation to the ischemic 
lesion on coronal sections (Figure 5a). We observed reactive astrocytes with increased GFAP 
staining in the peri-lesion areas in WT samples, with an obvious increase at 3 dpi compared to 6 
and 24h. Interestingly, the Cav-1 KO mice did not display such a noticeable increase in GFAP 
labeling in the ischemic peri-lesion at 3 dpi nor at earlier time points. Cell proliferation revealed 
by the Ki67 marker identified some new cells as GFAP positive cells indicating the proliferation of 
reactive astrocytes in the peri-lesion (Figure 5b). We analyzed possible morphological differences 
in GFAP-positive astrocytes and their processes between the two groups of mice on images at 
higher magnification (40x). GFAP images were taken from z-projections made from stacks of 
images that were filtered (Figure 5c) and skeletonized. In the Cav-1 KO mice, the GFAP 
immunolabelled reactive astrocytes showed a distinct morphology to the WT group, with shorter 
processes (arrowheads) and less branches. We confirmed this visual impression by morphology 
analysis (Figure 5d). The total number of GFAP positive cells was changed between the groups 
 
 
with more astrocytes in the Cav-1 KO group compared to the WT (t=2.196, p=0.0372). The 
number of endpoints of the astrocytes showed a tendency to decrease in Cav-1 KO images 
compared to WT (t=1.893, p=0.0695). Similarly, the total length of astrocyte branches (272 ± 
42.77 for WT versus 239 ± 30.5 for Cav-1 KO) and the maximum branch length (48.66 ± 6.25 for 
WT versus 41.21 ± 6.86 for Cav-1 KO) were significantly decreased in the Cav-1 KO animals 
(t=2.498, p=0.0192 and t=2.897, p=0.0076 respectively, n= 4 images per animal in n=3 animals 
per group).  
All together, these results point towards a change in the pattern and the distribution of reactive 




The NVU has been proposed as a key element for future development of new treatments for 
stroke and other brain disorders5. We and others previously showed changes of Cav-1 expression 
in the NVU in various brain disorders12, 19, 27, however, the changes in Cav-1 expression and the 
role of the protein in stroke is not clear at present7. To address this question, we studied changes 
in Cav-1 expression in the NVU over time after tMCAO, then compared the functional outcome 
as well as changes at the cellular level in WT and genetically modified Cav-1 KO mice. Overall, 
in this study, the absence of Cav-1 is associated with (1) an increased mortality and a larger lesion 
volume after tMCAO, (2) a more severe functional outcome with sensorimotor deficits assessed 
by the neuroscore, rotarod and adhesive removal test behavioral tests, (3) increased - 
proliferation of endothelial cells, (4) changes in reactive astrocytes morphology and distribution in 
the peri-lesion. The results presented here provide several novel and important findings regarding 
the behavior and the role of astrocytes in Cav-1 KO mice after ischemic stroke. One of the 
important findings in the present study is the modification of reactive astrocyte morphology and 
distribution in the absence of Cav-1. 
We believe that the presence of Cav-1 is important for limiting the progression of the pathology 
after stroke onset by facilitating (1) neovascularization in the ischemic lesion and (2) astrogliosis 
and scar formation in the perilesional tissue which has never been considered after stroke so far 
(Figure 6). Our work suggests a decisive role of Cav-1 in these two processes contributing to 
tissue repair.  
 
Presence of Cav-1 benefits recovery post-stroke: 
 Various studies have shown changes in Cav-1 expression in several preclinical models 
of brain disorders with a dual interpretation of its role7, 18. This is true for stroke research where 
preclinical studies used a variety of animal models with conflicting results reporting deleterious or 
beneficial roles of Cav-1 after stroke. Here we chose the filament tMCAO model as the middle 
cerebral artery is the most commonly affected blood vessel in human ischemic stroke28 and this 
 
 
model has been used in many studies addressing pathophysiological processes or 
neuroprotective agents22. This model is also more physiological than the previously used model19 
of permanent distal MCAO which requires a craniotomy and can therefore impact early post-
stroke behavioral assessment. Different lengths of occlusion have been tested in our lab and the 
35 minutes occlusion was determined as a good compromise between variability of lesion sizes 
and severity in the C57Bl6/J WT mice. In this model, Cav-1 KOs displayed larger lesion sizes at 
time of sacrifice compared to WTs, suggesting a beneficial role of Cav-1 in tMCAO. We observed 
a difference between groups as early as 6 hours after injury, with a more prominent loss of 
neurons in the absence of Cav-1.  
 The major preclinical outcome measures for stroke pharmacotherapy studies are final 
lesion size and sensorimotor neurological deficits. The latter are more clinically relevant and also 
more challenging to accurately assess as deficits can rapidly resolve in rodent models9. A broad 
variety of tests have been described to assess post-stroke deficits25. To our knowledge, we are 
the first to assess and describe sensorimotor deficits in Cav-1 KO mice following stroke. We chose 
three tests (Neuroscore, rotarod and adhesive removal) in order to discriminate between general 
neurological deficits (neuroscore), locomotor activity (rotarod) and fine movements (adhesive 
removal). In the Cav-1 KO group, at all time points, the neuroscore was worse, the time to fall 
from the rotarod shorter and the time to contact and remove the adhesive longer than in the WT 
group. Overall, these three outcome assessments highlighted greater sensorimotor deficits for 
the Cav-1 KO group in agreement with the large lesion volumes. Others have reported 
neurological abnormalities including clasping, abnormal spinning, muscle weakness, reduced 
activity and gait abnormalities in Cav-1 KO mice29, 30. However, we did not observe this and found 
no significant differences in the three behavioral tests used in this study between WT and Cav-1 
KO mice after sham injuries (Supplementary Figure 4).  
Our results are in agreement with a previous study19 where Cav-1 KO mice had increased lesion 
volumes at a short time point in a model of permanent distal MCAO (MCA sutured locally after a 
craniotomy). In the cited work, the authors suggested an important role of increased Cav-1 at 48h, 
 
 
and at 1 and 2 weeks in tissue protection, with a significant decrease in apoptosis, a significant 
increase in neovascularization as well as an increase of the number of proliferative endothelial 
cells in the lesion core. However, in a rat model of 2h tMCAO others obtained opposite results 
showing decreased Cav-1 expression at 24, 48 and 72h in the ipsilateral hemisphere17. In their 
study, the decrease in Cav-1 expression was associated with an increase in metalloproteinase 
activity at 24h after a 15 min tMCAO in Cav-1 KO mice17. The discrepancy between our results 
and Gu and collaborators17 may be explained by variations in the experimental protocols such as 
the occlusion time (35min, 1 hour, 3 hours), as well as using two different stroke models in two 
different species (rat and mouse) as well as the immunoblot analysis of homogenates of the entire 
ischemic hemisphere versus homogenates of the ischemic core only. In summary, our behavioral 
outcomes after stroke support the idea that endogenous Cav-1 plays a beneficial role in limiting 
the extension of the lesion after 35 min tMCAO in mice.  
 
Benefit from post-stroke neovascularization:  
 Studies showed Cav-1 expression in various cell types of the neurovascular unit. In a 
juvenile rat TBI model, we previously showed an increase in Cav-1 expression in endothelial cells 
and astrocytes12. Observing a decrease in survival of Cav-1 KO animals at 3 to 4 days after TBI 
and significant signs of recovery in WT animals in the behavioral tests, we explored the 
localization of Cav-1 protein here at 3 days after tMCAO by immunofluorescence staining in WT 
animals. Cav-1 was present in CD31 positive endothelial cells. This result is in agreement with 
previous work, as endothelial cells are one of the cell populations that express the highest level 
of caveolae and Cav-1 and caveolae are thought to constitute up to 30% of the total endothelial 
cell surface in capillaries7. Interestingly, the ischemic hemisphere appeared to have increased 
expression of Cav-1 after stroke compared to contralateral hemisphere. This was also seen in 
previous studies showing increased Cav-1 expression in the ischemic hemisphere after 
photothrombotic ischemia in mice27 and tMCAO in rats19. But this needed to be confirmed with 
the more physiological tMCAO model of stroke in mice. Previous studies extensively investigated 
 
 
the correlation between BBB protection against disruption and Cav-1 expression and thus offering 
Cav-1 a protective role against BBB breakdown during focal cerebral ischemia27. The deficiency 
of neovascularization in Cav-1 KO mice has already been assessed in a permanent cerebral 
ischemia model of distal ligation of the MCA19 and in a hindlimb ischemia model31. In the work by 
Jasmin et al, 2007, PCNA (proliferating cell nuclear antigen)-positive blood vessels were labeled 
with laminin belonging to the perivascular matrix. Here we present another MCAO model and 
another marker of cell proliferation, Ki67, to confirm these results. In our tMCAO model, we 
observed endothelial cell proliferation in the ischemic lesion in both groups of animals (Figure 4a-
d) in agreement with previous studies7. However, Cav-1 KO mice exhibited significantly less 
neovascularization with fewer Ki67-positive endothelial cells compared to WT and decreased 
vessel density. This suggests a lower number of new endothelial cells in the ischemic lesion when 
Cav-1 is absent. Neovascularization is a dynamic process of endothelial proliferation, migration 
and differentiation and a well-established event occurring in the ischemic lesion7. It is essential 
for brain recovery as it stimulates blood flow, collateralization and neuroplasticity31. The impaired 
neovascularization might contribute to the increased ischemic injury observed in Cav-1 KO mice. 
Mechanistically, Cav-1 could act as a “differentiation sensor” to directly modulate regulators of 
neovascularization, such as vascular endothelial growth factor (VEGF), produced by the 
astrocytes and eNOS to coordinate proliferation and differentiation of endothelial cells7.  
 
 
Benefit from post-stroke astrogliosis:  
Some studies showed Cav-1 in astrocyte cultures in vitro10, 11 and in an in vitro model of ischemia 
reperfusion (oxygen glucose deprivation/ reoxygenation: OGD-R). To our knowledge, apart from 
our previous study showing localization of Cav-1 protein in rat astrocytes after juvenile TBI in 
vivo12 we show here for the first time Cav-1, localization in adult mice astrocytes positive for GS 
and GFAP after ischemic stroke (Figure 1d-g). However, the emerging view is that astrocytes 
constitute a heterogeneous population8 and the role of Cav-1 in astrocytes is unknown in both 
 
 
normal and pathological brain tissue. Astrogliosis is defined as the response of astrocytes to all 
forms of brain stress, damage and disease with particular changes in gene expression, cellular 
structure and functions8. Marked diffuse reactive astrogliosis is generally found in areas 
surrounding severe focal lesions forming a glial scar33. This is thought of as part of the first phase 
after focal injury such as ischemia, comprising cell death and inflammation34 and may have 
beneficial effects on brain injury outcome, including neuronal protection, BBB repair and 
restriction of inflammation35. However, the role of Cav-1 in astrocytes has never been considered 
after ischemia. Notably, we show here morphological differences in reactive astrocytes in the 
absence of Cav-1. Specifically, the ramification pattern was different between the WT and Cav-1 
KO mice with a significant decrease in the total length of segments and the maximum branch 
length in Cav-1 KO mice. The low level of ramification and process complexity of the Cav-1 KO 
astrocytes could prevent scar formation. We observed better recovery of WT mice at 3 dpi in 
behavioral tests while Cav-1 KO animals had sparse reactive astrocytes and absence of a glial 
scar and reactive morphology in the ischemic peri-lesion. One other study also found less 
astroglial differentiation in the dentate gyrus of adult Cav-1 KO mice36 indicating that genetic 
ablation of Cav-1 may directly inhibit the formation of new  reactive astrocytes and be detrimental 
to the ischemic injury. While traditionally viewed as a barrier to axon regeneration, beneficial 
functions of the glial scar have recently been identified37. An emerging concept is that astrocytic 
scar could actually aid central nervous system regeneration. In a model of spinal cord injury (SCI), 
RNA sequencing revealed that astrocytes and non-astrocyte cells in SCI lesions express multiple 
axon-growth-supporting molecules and by contrast preventing astrocytic scar formation 
significantly reduced this stimulated axon regrowth38. The glial scar has been widely studied in 
the context of SCI, but it also occurs after traumatic brain injury and ischemic stroke and more 
work is needed in these models.  
Although several studies already investigated Cav-1 signaling pathways of in astrocytes in vitro39-
41, the mechanism by which Cav-1 regulates astrogliosis is still unclear. In an in vitro model of 
ischemia – reperfusion (OGD-R), a recent study suggested that basic fibroblast growth factor 
 
 
(bFGF) might protect astrocytes from injury by up-regulating the Cav-1/VEGF signaling 
pathway41. In addition to the roles of the Cav-1/VEGF signaling pathway in neovascularization 
and neurogenesis, it may be also involved in astrogliosis, astroglial scar formation and 
neuroinflammation after cerebral ischemia41.  
 
Limitations 
There are several limitations to the present study. In particular, in-depth mechanistic as to how 
Cav-1 promotes revascularization and inhibits astrogliosis after stroke remain to be investigated. 
Also, so far only the full Cav-1 KO mouse model is available but to prove a primary role of Cav-1, 
deletion of Cav-1 at a delayed time point after infarct resolution using a tamoxifen-inducible 
conditional deletion of Cav-1 would be very interesting. Likewise, manipulation by specific knock-
out or overexpression of Cav-1 in an endothelial-specific manner to rescue revascularization and 
astrocyte-specific targeting astrogliosis could be interesting approaches. 
 
Summary 
Altogether, characterization of Cav-1 KO mice brings insight into the role of Caveolin-1 in brain 
injuries. In this study, we focused on endothelial cells and astrocytes of the neurovascular unit, 
for a novel perspective on approaches against ischemia injury. We saw better survival after stroke 
and better recovery of sensorimotor deficits if Cav-1 was present. These results point towards a 
potential protective role of endogenous Cav-1 in the neurovascular unit in the first days after 
stroke. Our hypothesis is that via its signaling functions, Cav-1 and caveolae formation could play 
a role in BBB repair, neovascularization and astrogliosis after ischemic injury. A key protein in 





This work was partly supported by the Swiss National Science Foundation 31003A_163465 / 1 
(LH, JB), Eranet Neuron TRAINS (JB); TRAIL- Laboratory of Excellence TRAIL (ANR-10-LABX-
57 to JB) 
The authors thank Leonardo Restivo for his help in the behavioral tests and analysis using the 
NeuroBAU behavioral platform of the department of Fundamental Neurosciences of Unil, 
Lausanne, Switzerland. 
The author also acknowledge the Cellular Imaging Facility (CIF) for the imaging support. 
 
Author Contribution statement 
CB, LB, JB and LH contributed to conception and design of the study. CB acquired the data and 
CB, LB, SG and TC analyzed the data. CB, JB, LB and LH drafted a significant portion of the 
manuscript and figures. JB and LH contributed equally to this work and share last authorship. All 
authors read and approved the final version of the manuscript. The authors thank Melanie Price 
for her help with carefully reading and editing the manuscript.  
 
Disclosure of conflicting interest 
The authors declare that there is no conflict of interest. 
 
Supplementary material 
Supplementary material for this paper is available at: 






1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 
Update: A Report From the American Heart Association. Circulation 2016; 133: e38-360. 
2015/12/18. DOI: 10.1161/CIR.0000000000000350. 
2. Meadows KL. Experimental models of focal and multifocal cerebral ischemia: a review. 
Rev Neurosci 2018 2018/02/06. DOI: 10.1515/revneuro-2017-0076. 
3. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-
vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. 
The Lancet 2016; 387: 1723-1731. DOI: 10.1016/s0140-6736(16)00163-x. 
4. Neuhaus AA, Couch Y, Hadley G, et al. Neuroprotection in stroke: the importance of 
collaboration and reproducibility. Brain : a journal of neurology 2017; 140: 2079-2092. 
2017/06/24. DOI: 10.1093/brain/awx126. 
5. Zhang JH, Badaut J, Tang J, et al. The vascular neural network--a new paradigm in 
stroke pathophysiology. Nat Rev Neurol 2012; 8: 711-716. 2012/10/17. DOI: 
10.1038/nrneurol.2012.210. 
6. Persidsky Y, Ramirez SH, Haorah J, et al. Blood-brain barrier: structural components 
and function under physiologic and pathologic conditions. Journal of neuroimmune 
pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2006; 1: 223-
236. 2007/11/28. DOI: 10.1007/s11481-006-9025-3. 
7. Xu L, Guo R, Xie Y, et al. Caveolae: molecular insights and therapeutic targets for 
stroke. Expert Opin Ther Targets 2015; 19: 633-650. DOI: 10.1517/14728222.2015.1009446. 
8. Sofroniew MV. Astrogliosis. Cold Spring Harb Perspect Biol 2014; 7: a020420. 
2014/11/09. DOI: 10.1101/cshperspect.a020420. 
9. Hnasko RL, M. P. The Biology of Caveolae: Lessons from Caveolin Knockout Mice and 
Implications for Human Disease. Mol Interv 2003; 3: 20. 
10. Ikezu T, Ueda H, Trapp BD, et al. Affinity-purification and characterization of caveolins 
from the brain: differential expression of caveolin-1, -2, and -3 in brain endothelial and astroglial 
cell types. Brain Res 1998; 804: 177-192. 1998/12/05. 
11. Cameron PL, Ruffin JW, Bollag R, et al. Identification of caveolin and caveolin-related 
proteins in the brain. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 1997; 17: 9520-9535. 1998/01/10. 
12. Badaut J, Ajao DO, Sorensen DW, et al. Caveolin expression changes in the 
neurovascular unit after juvenile traumatic brain injury: signs of blood-brain barrier healing? 
Neuroscience 2015; 285: 215-226. 2014/12/03. DOI: 10.1016/j.neuroscience.2014.10.035. 
13. Stern CM and Mermelstein PG. Caveolin regulation of neuronal intracellular signaling. 
Cell Mol Life Sci 2010; 67: 3785-3795. 2010/07/16. DOI: 10.1007/s00018-010-0447-y. 
14. Razani BW, S. E.; Lisanti, M. P. Caveolae: From Cell Biology to Animal Physiology. 
Pharmacological review 2002; 54: 37. 
15. Okamoto T, Schlegel A, Scherer PE, et al. Caveolins, a family of scaffolding proteins for 
organizing "preassembled signaling complexes" at the plasma membrane. The Journal of 
biological chemistry 1998; 273: 5419-5422. 1998/04/16. 
16. Garcia-Cardena G, Martasek P, Masters BS, et al. Dissecting the interaction between 
nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding 
domain in vivo. The Journal of biological chemistry 1997; 272: 25437-25440. 1997/11/05. 
17. Gu Y, Zheng G, Xu M, et al. Caveolin-1 regulates nitric oxide-mediated matrix 
metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and 
reperfusion injury. Journal of neurochemistry 2012; 120: 147-156. 2011/10/20. DOI: 
10.1111/j.1471-4159.2011.07542.x. 
18. Gu Y, Dee CM and Shen J. Interaction of free radicals, matrix metalloproteinases and 
caveolin-1 impacts blood-brain barrier permeability. Frontiers in bioscience (Scholar edition) 
2011; 3: 1216-1231. 2011/05/31. 
 
 
19. Jasmin JF, Malhotra S, Singh Dhallu M, et al. Caveolin-1 deficiency increases cerebral 
ischemic injury. Circulation research 2007; 100: 721-729. 2007/02/13. DOI: 
10.1161/01.res.0000260180.42709.29. 
20. Knowland D, Arac A, Sekiguchi KJ, et al. Stepwise recruitment of transcellular and 
paracellular pathways underlies blood-brain barrier breakdown in stroke. Neuron 2014; 82: 603-
617. DOI: 10.1016/j.neuron.2014.03.003. 
21. Pawson T and Scott JD. Signaling through scaffold, anchoring, and adaptor proteins. 
Science 1997; 278: 2075-2080. 1998/02/12. 
22. Fluri F, Schuhmann MK and Kleinschnitz C. Animal models of ischemic stroke and their 
application in clinical research. Drug Des Devel Ther 2015; 9: 3445-3454. 2015/07/15. DOI: 
10.2147/DDDT.S56071. 
23. Bederson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of 
the model and development of a neurologic examination. Stroke 1986; 17: 472-476. 
24. Hirt L, Badaut J, Thevenet J, et al. D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase 
inhibitor, protects against cell death in severe cerebral ischemia. Stroke 2004; 35: 1738-1743. 
DOI: 10.1161/01.STR.0000131480.03994.b1. 
25. Balkaya M, Krober JM, Rex A, et al. Assessing post-stroke behavior in mouse models 
of focal ischemia. J Cereb Blood Flow Metab 2013; 33: 330-338. 2012/12/13. DOI: 
10.1038/jcbfm.2012.185. 
26. Morrison H, Young K, Qureshi M, et al. Quantitative microglia analyses reveal diverse 
morphologic responses in the rat cortex after diffuse brain injury. Scientific reports 2017; 7: 
13211. 2017/10/19. DOI: 10.1038/s41598-017-13581-z. 
27. Choi KH, Kim HS, Park MS, et al. Regulation of Caveolin-1 Expression Determines 
Early Brain Edema After Experimental Focal Cerebral Ischemia. Stroke 2016; 47: 1336-1343. 
2016/03/26. DOI: 10.1161/strokeaha.116.013205. 
28. Macrae IM. Preclinical stroke research – advantages and disadvantages of the most 
common rodent models of focal ischaemia. British Journal of Pharmacology 2011; 164. DOI: 
10.1111/bph.2011.164.issue-4. 
29. Trushina E, Du Charme J, Parisi J, et al. Neurological abnormalities in caveolin-1 knock 
out mice. Behavioural brain research 2006; 172: 24-32. DOI: 10.1016/j.bbr.2006.04.024. 
30. Gioiosa L, Raggi C, Ricceri L, et al. Altered emotionality, spatial memory and 
cholinergic function in caveolin-1 knock-out mice. Behavioural brain research 2008; 188: 255-
262. 2007/12/18. DOI: 10.1016/j.bbr.2007.11.002. 
31. Zhang ZG and Chopp M. Neurorestorative therapies for stroke: underlying mechanisms 
and translation to the clinic. The Lancet Neurology 2009; 8: 491-500. DOI: 10.1016/s1474-
4422(09)70061-4. 
32. Sonveaux P, Martinive P, DeWever J, et al. Caveolin-1 expression is critical for vascular 
endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated 
angiogenesis. Circulation research 2004; 95: 154-161. 2004/06/19. DOI: 
10.1161/01.RES.0000136344.27825.72. 
33. Sofroniew MV and Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 
2010; 119: 7-35. 2009/12/17. DOI: 10.1007/s00401-009-0619-8. 
34. Burda JE and Sofroniew MV. Reactive gliosis and the multicellular response to CNS 
damage and disease. Neuron 2014; 81: 229-248. 2014/01/28. DOI: 
10.1016/j.neuron.2013.12.034. 
35. Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci 2015; 
16: 249-263. 2015/04/22. DOI: 10.1038/nrn3898. 
36. Li Y, Lau WM, So KF, et al. Caveolin-1 promote astroglial differentiation of neural 
stem/progenitor cells through modulating Notch1/NICD and Hes1 expressions. Biochem 
Biophys Res Commun 2011; 407: 517-524. 2011/03/19. DOI: 10.1016/j.bbrc.2011.03.050. 
37. Adams KL and Gallo V. The diversity and disparity of the glial scar. Nat Neurosci 2018; 
21: 9-15. 2017/12/23. DOI: 10.1038/s41593-017-0033-9. 
 
 
38. Anderson MA, Burda JE, Ren Y, et al. Astrocyte scar formation aids central nervous 
system axon regeneration. Nature 2016; 532: 195-200. 2016/03/31. DOI: 10.1038/nature17623. 
39. Jo A, Park H, Lee SH, et al. SHP-2 binds to caveolin-1 and regulates Src activity via 
competitive inhibition of CSK in response to H2O2 in astrocytes. PloS one 2014; 9: e91582. 
2014/03/19. DOI: 10.1371/journal.pone.0091582. 
40. Xu L, Wang L, Wen Z, et al. Caveolin-1 is a checkpoint regulator in hypoxia-induced 
astrocyte apoptosis via Ras/Raf/ERK pathway. American journal of physiology Cell physiology 
2016; 310: C903-910. 2016/03/25. DOI: 10.1152/ajpcell.00309.2015. 
41. Liu M, Wu Y, Liu Y, et al. Basic Fibroblast Growth Factor Protects Astrocytes Against 
Ischemia/Reperfusion Injury by Upregulating the Caveolin-1/VEGF Signaling Pathway. J Mol 






Figure 1. (a) Western blot showing the 20 kD band of Cav-1 in WT sham and tMCAO ipsilateral 
(tMCAO Ipsi) and contralateral (tMCAO Contra) side to the lesion, α-Tubulin band at 50 kD used 
as control for n=3 animals per condition. Quantification using the mean grey value and normalized 
against the mean value for Sham. (b) Caveolin-1 expression after tMCAO in relation to the lesion 
as shown in neuronal MAP-2 staining on a coronal section. (c) Cav-1 (green) co-localizes with 
CD31-labeled (red) endothelial cells in the striatum ipsilateral (left panel) and contralateral (right 
panel) to the ischemic lesion at 3 dpi. (d) In the ipsilateral (left panel) and in the contralateral 
hemisphere (right panel), Cav-1 (green) was also observed (arrowheads) in the GS-positive 
astrocytes (red). (e) In the peri-lesion region next to the ventricle (left panel) and in the striatum 
contralateral to the lesion (right panel), Cav-1 (green) was found to co-localize (arrows) in reactive 
astrocytes stained with GFAP (red). Respective control staining were made using the same 
markers on Cav-1 KO tissue and are available in supplementary figure 1. Scale bar = 20 µm.  
 
Figure 2. Survival and lesion size assessment after 35 min tMCAO in WT and Cav-1 KO mice. 
Kaplan-Meier survival plot and (b) lesion size at time of sacrifice measured from cresyl violet 
staining (not shown), box plot show the mean lesion volume ± min/max for WT and Cav-1 KO 
mice after 35 min tMCAO surgery and the dots individual animals with the time of sacrifice 
specified on the x-axis. (c) Immunofluorescence staining using MAP-2 (neuronal marker) on 
coronal slices of WT and Cav-1 KO mice after tMCAO or sham surgery collected respectively 6 
hours, 24 hours and 3 days after stroke, lesion delimited by yellow dotted line. Scale bar = 1mm 
 
Figure 3. Behavioral assessment (a) Neuroscore assessed on a scale from 0 (no deficit) to 3 
(sacrifice) at 1, 4 and 7 dpi. (b) Latency to fall from the Rotarod apparatus expressed as percent 
of the best baseline performance value (mean ± SD). (c) Time before contact and (d) before 
removal of the adhesive placed under each paw of the mouse assessed at 2, 4 and 6 dpi and 
 
 
expressed as the difference between best baseline performance and best test time for each 
mouse (mean ± SD). 
 
Figure 4. Neovascularization in the lesion. (a-d) Immunofluorescence staining with Ki67 (green) 
and CD31 (red) in WT (a, c) and Cav-1 KO (b, d) mice at 3 days post-MCAO. Scale bar = 1mm. 
(e) Immunofluorescence staining with Ki-67 (green), CD31 (red) and DAPI counterstaining (blue) 
in the striatum ipsilateral to the lesion in the WT (left image) and in the Cav-1 KO (right image), 
scale bar = 20 µm. (f) Quantification of the vessel density showing the ratio of vasculature area 
to the total image area (individual points, mean and SD) in WT and Cav-1 KO images (g) 
Quantification (individual points, mean and SD) of the total number of nuclei stained with Ki67 per 
area (left plot) and the number of nuclei labeled by Ki67 in the vessels per area (right plot) in WT 
and Cav-1 KOs. n=3 areas per animal with 3 animals per group, 20x sections. 
 
Figure 5. (a) Astrocyte reactivity time-course on coronal brain sections from WT and Cav-1 KO 
mice stained with GFAP and MAP-2. Sections were collected for sham animals and 6 hours, 1 
and 3 days after tMCAO. Scale bar = 1mm (b) Immunofluorescence staining with proliferating 
cells marker Ki67 (green), reactive astrocytes marker GFAP (red) and DAPI nuclei counterstaining 
(blue) in the striatum ipsilateral to the lesion in the WT (top image) and in the Cav-1 KO (bottom 
image), scale bar = 20 µm (c) High magnification (40x) panels on sections obtained at 3 dpi 
illustrating GFAP positive reactive astrocytes (stained in white on black background) in the striatal 
peri-lesion in WT (top image) and Cav-1 KO )bottom image), scale bar = 20 µm. Inserts with zoom 
on a single astrocyte from each group. (d) Analysis of astrocytes number and astrocytic 
morphology by skeletonization: plot of the number of GFAP-positive cells, number of endpoints, 
total length of the segment and the maximum branch length in WT and Cav-1 KO astrocytes in 




Figure 6. Summary figure of the differences observed between WT and Cav-1 KO mice. 
Increased lesion size associated with behavior dysfunction such as sensorimotor deficits were 
observed in parallel to impaired neovascularization in the core of the lesion and impaired 
astrogliosis more specifically changes in the astrocytes morphology preventing the scar formation 




Supplementary Figure 1. Negative controls for the Caveolin-1 expression after tMCAO 
showed in Figure 1. Immunostaining on Cav-1 KO samples showing none or non-specific 
staining with Cav-1 (green) and no co-localization with CD31-labeled (red) endothelial cells, 
astrocytes stained with GS in the striatum ipsilateral (left panel) and contralateral (right panel) to 
the ischemic lesion at 3 dpi and astrocytes stained with GFAP in the perilesion. A negative control 
is also provided using the secondary antibodies alone for the same conditions. Scale bar = 20 
µm.  
Supplementary Figure 2. Caveolin-1 expression after tMCAO in neurons. Triple 
immunostaining of Cav-1 (green) and Iba-1 microglial marker (red) and neurons stained with 
NeuN (grey). Co-localization between Cav-1 can be observed with neurons in the peri-lesion (right 
panel) showed with yellow arrows but not in microglia. Scale bar = 20 µm.  
 
Supplementary Figure 3. Comparison of the behavioral tests performed in WT and Cav-1 KO 
mice after sham injury. (a) Latency to fall from the Rotarod apparatus expressed as percent of 
the best baseline value before sham surgery. (b) Time before contact and (c) before removal of 
the adhesive placed under each paw of the mouse assessed on days 2, 4 and 6 after sham 
surgery and expressed as the difference between best baseline and best test time for each 
mouse. No significant difference was found in the two-way ANOVA with repeated measures. 
(mean ± SD) 
 
 
Supplementary Figure 4. Neuroscore assessed on a scale from 0 (no deficit) to 3 (sacrifice) on 
each day following stroke until planned sacrifice at day 7 post-tMCAO. No significant difference 
was highlighted by the 2-way ANOVA with repeated measures. 
 
Supplementary Figure 5. Identification of the other cell types stained for Ki67. Triple 
immunostaining with Ki67 (green), Iba1 (red), GFAP (grey) and nuclear counter-staining with 
DAPI (blue) in the periphery of the lesion showing new proliferating microglial cells stained with 
Iba1 in the lesion and Ki67 (white arrows) as well as new proliferating reactive astrocytes GFAP 
and Ki67 positive (yellow arrowheads) in the peri-lesion for the WT (left panel) and the Cav-1 KO 
(right panel).  
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